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ABSTRACT 
 
Breaking the Rules: Increased Invasive Aggression in Chemo-Resistant Lymphoma. 
(April 2010) 
 
Evan Michael Cherry 
Department of Chemical Engineering 
Texas A&M University 
 
Research Advisors: Dr. Kayla Bayless, Dr. Steve Maxwell 
Department of Molecular & Cellular Medicine 
 
Diffuse Large B Cell Lymphoma (DLBCL) is a common form of cancer, accounting for 
30% of all lymphoma diagnoses. Patient survival rates of DLBCL are roughly 30-40% 
with the standard chemotherapeutic cocktail consisting of cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP therapy). Approximately 50% of 
patients develop chemoresistance to CHOP therapy and succumb to metastasis of vital 
organs. To penetrate tissues and organs, lymphoma cells must invade the extracellular 
matrix surrounding blood vessels. We investigated the ability of CHOP-resistant 
lymphoma to invade three-dimensional collagen matrices mimicking the extracellular 
matrix. We evaluated the potential for cellular dyes to quantify invasion responses and 
developed a protocol for automated fluorescent quantification of invasion responses. 
Further, because the cytoskeleton is critical for cell locomotion and morphology, we 
investigated the role of key cytoskeletal proteins vimentin, actin, and tubulin in 
lymphoma invasion. Our data indicate that microtubule stabilization, but not 
  iv 
depolymerization, inhibits CHOP-resistant lymphoma invasion. Additionally, 
depolymerization of actin and vimentin completely blocked invasion responses. 
Altogether, this work develops a quantifiable model to study lymphoma invasion, mimic 
metastasis, understand cytoskeletal function, and gain further insight into molecular 
signals required for cellular invasion in three-dimensional matrices. 
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NOMENCLATURE 
 
AB Alamar Blue (Resazurin) 
bFGF Basic Fibroblast Growth Factor 
CHOP Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and 
Prednisone 
CT488 Celltrace Oregon Green 488 
DiI 1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine 
perchlorate 
DLBCL Diffuse Large B Cell Lymphoma 
EGF Epidermal Growth Factor 
FACS Fluorescence-Activated Cell Sorting 
FBS Fetal Bovine Serum 
GFP Green Fluorescent Protein 
HPLC High-Performance Liquid Chromatography 
IGF Insulin-like Growth Factor 
LPA Lysophosphatidic Acid 
MMP Matrix Metalloproteinase 
MTT Dimethyl thiazolyl diphenyl tetrazolium 
PBS Phosphate-Buffered Saline 
K Thousand 
RFU Relative Fluorescence Unit 
  vii 
RPMI Roswell Park Memorial Institute Medium 1640 
S1P Sphingosine-1-Phosphate 
UV Ultraviolet 
VEGF Vascular Endothelial Growth Factor 
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CHAPTER I 
INTRODUCTION 
 
Diffuse large B cell lymphoma and non-Hodgkins lymphoma 
Lymphoma is a type of cancer that originates in the immune system due to malignant 
lymphocytes. Lymphocytes such as T and B cells are types of white blood cells that 
mediate the active immune response.  Lymphoma was first discovered and characterized 
by Thomas Hodgkin, a british physician, who noticed tumor growth in lymph tissue [1].  
 
Non-Hodgkins Lymphoma is a class of lymphoma encompassing strains other than those 
described by Thomas Hodgkin in 1832 [2]. Classes of Lymphoma are divided based on 
lymphocyte origin as well as cell size and shape. Lymphoma classes can be further 
divided into subclasses based on specific genetic irregularities that cause lymphoma. 
Diffuse Large B Cell Lymphoma (DLBCL) is a very aggressive strain of non-Hodgkins 
lymphoma, caused by malignant B cells. DLBCL is the most prevalent strain of non-
Hodgkins Lymphoma, accounting for more than 30% of all diagnoses.  
 
CHOP and chemotherapy resistance 
Metastasis occurs due to the accumulation and invasion of cancer cells into nearby 
_______________ 
This thesis follows the style of Biophysical and Biochemical Research Communications. 
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tissues, ultimately leading to patient mortality. To combat malignant cells 
chemotherapeutic agents target rapidly dividing cells. One major strategy is to disrupt 
the cells’ ability to rearrange their cytoskeleton, arrest the cell in a non-metabolic period, 
prevent the cell from dividing, and kill the cell [3]. However, cancerous cells eventually 
become chemo-resistant, even to high-dose regimens [4]. These mechanisms of chemo-
resistance require new treatments for preventing the spread and proliferation of cancer 
cells. 
 
CHOP, a combination of Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), 
Oncovin (Vincristine), and Prednisone, is the standard strategy for treating DLBCL 
because it is as effective as and less toxic than other chemotherapy regimens [5-6]. The 
survival rate of non-Hodgkins Lymphoma with CHOP therapy is roughly 30-40%, but 
when the patient becomes CHOP-resistant, the survival rate plummets [7].  
 
Cellular invasion 
Cellular invasion is an otherwise normal physiological process, applicable to wound 
healing, angiogenesis (blood vessel formation), and the immune response. In the 
immune response, signaling lipids such as lysophosphatidic acid (LPA) and sphingosine-
1-phosphate (S1P) encourage lymphocyte proliferation and migration [8-10]. 
Additionally, signaling peptides (mitogens) called growth Factors (GFs) are usually 
required to activate proteins that signal for cell motility [11].  
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The most visible aspect of cellular motility and invasion is morphology changes due to 
reorganization of the cytoskeleton, roughly analogous to muscle and bone movement in 
higher organisms. Specifically, three types of cytoskeletal elements are important to cell 
shape and motility: microtubules, microfilaments, and intermediate filaments [12]. Cell 
morphology change is a dynamic process in the invasion response, as we have 
demonstrated with endothelial cells in (Fig. 1) [13].  
Fig. 1. Endothelial cells invade 3-dimensional collagen matrices. 
The cytoskeletal protein tubulin is the target for many therapies, including treatment for 
cancer and gout.  Physiological levels for cytoskeletal drugs vincristine (Fig. 2A), 
colchicine (Fig. 2B), and paclitaxel (Fig. 2C) have been determined from HPLC [14-16] 
and will be used at these concentrations in our enclosed studies on drug-resistant parent 
cell lines generated previously in the laboratory [17].  
 
Fig. 2. Cytoskeletal drugs vincristine (A), colchicine (B), and paclitaxel (C). 
0 hr 6 hr 12 hr 18 hr 
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CHAPTER II 
METHODS 
 
Reagents 
All reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.  
 
Collagen extraction 
Rat tail collagen type I was isolated by soaking frozen rat tails in ethanol, removing the 
epidermis from the tails, extracting tendons, and removing any muscle or fatty tissue. 
Tendons were then soaked in 150 ml of sterile 0.1% (vol/vol) acetic acid and gently 
shaken for 48 hours. Every 24 hours thereafter the solution was centrifuged and 40 ml 
extracts were removed from the supernatant and added to separate tubes. Extracts were 
combined in a lyophilizer bottle and rotated while shell-freezing in dry ice until all liquid 
was frozen. Frozen solution was lyophilized until dry product was white and fibrous. 
Dry collagen product was weighed and dissolved overnight in 0.1% acetic acid to a final 
solution of 7.1mg collagen/ml. 
 
Isolation of CHOP-resistant DLBCL cell lines  
Diffuse large B cell lymphoma line CRL2631 was obtained from the American Type 
Culture Collection. Cells were propagated in RPMI 1640 supplemented with 2 mM L-
glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM 
sodium pyruvate, and 10% fetal bovine serum. Cells were passaged every 2 to 3 days to 
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maintain a density between 1-2 x 106 cells/ml. Four to five T75 flasks each containing a 
total of 3 x 107 DLBCL cells in 30 ml of medium (1 x 106 cells/ml) were treated with on-
off cycles of CHOP exposure. The composition of CHOP consisted of 
cyclophosphamide, doxorubicin, vincristine, and prednisone at the clinical ratio of 
80/5.5/0.16/11.1, respectively, with the highest combined CHOP concentration set at 
1280 ng/ml and the lowest at 5 ng/ml. Cyclophosphamide and doxorubicin were 
dissolved in Millipore-purified water, vincristine was dissolved in methanol, and 
prednisone was dissolved in chloroform/ethanol (1:1). CHOP reagents were stored at -
80oC. Similar to patient CHOP regimens, cells were subjected to cycles of 5 day CHOP 
treatment followed by 21 days of recovery in the absence of CHOP. Cells were initially 
selected with several cycles of 80 ng/ml CHOP. After several on-off cycles in 80 ng/ml 
CHOP, viable cells were treated with several on-off cycles of a higher CHOP dose (160 
ng/ml). Cycling with CHOP was continued until a cell population emerged that could 
survive and recover from 5-day exposures to 640 ng/ml CHOP. Three independently 
derived CHOP-resistant populations (designated G1, G2, G3) were derived from the 
CRL2631 cell line. Cell line G2 was used for this project. 
 
Cell culture  
Lymphoma cultures were grown in  5-10 ml of RPMI 1640 (RPMI) containing 10% FBS 
(Cambrex), 0.01 mg/ml Gentamycin Reagent Solution (Invitrogen), 1X MEM Non-
essential Amino Acids (Invitrogen), 1mM Sodium Pyruvate (Invitrogen), and 1X 
Antibiotic-Antimycotic (Invitrogen) in 25 cm2 flasks (Corning Incorporated). 3-5 ml of 
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cell suspension were aspirated and replaced with fresh medium every 3-4 days. For 
invasion experiments, cells were counted with a hemacytometer, centrifuged, and 
resuspended in RPMI to 1x105 cells/50 µl unless otherwise indicated. 
 
Vertical collagen invasion assay 
1 mg/ml collagen matrices were prepared by combining 350 µl of 7.1 mg/ml collagen 
type I solution, 39 µl 10X M199, 2.1 µl 5N NaOH, and 2109 µl RPMI, keeping gel on 
ice and mixing thoroughly after adding each component. 28 µl of gel was added to wells 
in a 96-well plate (Corning Inc.) and allowed to polymerize and equilibrate at 37°C and 
5% CO2 for 10 min. G2 cells (100,000 cells/50 µl/well) were added to the wells and 
allowed to adhere. After seeding the cells, each well was given 50 µl of RPMI 
containing reduced-serum II supplement and the indicated concentrations of test 
compounds. Cells were allowed to invade for 48h before fluorescent staining. After 
quantification, cells were fixed in 3% glutaraldehyde in PBS and stained with 0.1% 
toluidine blue in 30% methanol before being counted using an eyepiece with an ocular 
grid. Three fields at the center of each triplicate were selected and counted manually at 
the specified magnification. Data is presented as invading cells per field (±SD). For 
cross-sectional photographs, gels were scored with a needle, placed on a microscope 
slide, cut into cross-sectional slices, and placed sideways. Pictures were taken and 
analyzed using an Olympus SC35 Type 12S Digital Camera and QCapture Pro Software 
(QImaging Co.).  
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Automated quantification 
At the end of 48h invasion, the culture media from the 96-well plate was tossed and the 
plate was submerged in sterile saline at 37oC and shaken vigorously/tossed 5-10 times. 
The saline was then tossed and each well was treated with indicated cellular label. 0.1% 
toluidine blue and 1.09 µM DAPI were added for 20 minutes and 24 hours, respectively, 
after fixing the cells for 20 minutes in 3% glutaraldehyde in PBS. Cells stained in 100 µl 
of RPMI with 20 µM DiI, 2 µM Celltrace Oregon Green 488 (Invitrogen), and 20µg/ml 
Texas Red-conjugated Lycopersicon esculentum (Tomato) Lectin (Vector Laboratories) 
were rotated at 37oC for 1h before reading. Cells stained with 20 µg/ml Alamar Blue 
(resazurin) were incubated at 37oC for 8-24h with special care to read the plate before all 
dye was metabolized. Fluorescence or absorbance was read using a Bio-TEK Synergy 
HT Plate reader and KC4 software. Absorbance, excitation, and emission wavelength 
settings are summarized in Table 1. 
Table 1. Absorbance and fluorescence settings for cellular dyes. 
Dye Absorbance 
(nm) 
Excitation 
(nm) 
Emission 
(nm) 
Toluidine 
Blue 
562   
DAPI  360/40 460/40 
DiI  530/25 590/20 
TR-Lectin  590/20 645/40 
CT488  485/20 528/20 
GFP  485/20 528/20 
Alamar 
Blue 
595 530/25 590/20 
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Generation of G2-GFP 
293FT cells were grown on 20 µg/ml collagen in DMEM with 10% FBS to full 
confluence. 293FT were transfected with lentiviral backbone and helper plasmids 
expressing GFP and blasticidin resistance for 8 hours. Viral particles were harvested 
after 72 h and combined 50:50 with RPMI with 10% FBS and 12 µg/ml polybrene. G2 
cells were treated with viral media for 48 h. GFP expression was verified by observing 
emission of green light when excited with 480nm UV light. Stable transfected cells were 
selected with blasticidin and sterile sorted by flow cytometry using a FACSAria II. The 
final population expressed greater than 9000 FITC-A units and reflected the 3.8% 
brightest GFP-expressing cells from the stable culture. 
 
Cytoskeletal altering compounds 
Microtubules were depolymerized using 1µM solutions of vincristine sulfate 
(Oncovin®) and vinblastine sulfate. To verify that the effects of vincristine and 
vinblastine on invasion were not due to drug resistance, cells were treated with 200nM 
of the non-vinca alkaloid microtubule depolymerizing agent colchicine.  Microtubules 
were stabilized with 1 µM paclitaxel (Taxol®). Actin and vimentin were depolymerized 
using 1 µM cytochalasin D and 1 µM withaferin A (EMD Biosciences), respectively. 
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CHAPTER III 
RESULTS 
 
We initially tested the invasion response of two lymphoma cell lines: CHOP-sensitive 
2631 and a CHOP-resistant progeny G3 [17]. Our initial experiments revealed that 
CHOP-resistant cells were notably more invasive than the CHOP-resistant parent line 
(Fig. 3A). Furthermore, the lymphoma cells are invading by changing their morphology 
to penetrate the gel (Fig. 3B). Through manually counting the number of invading cells, 
we determined that the average number of invading G3 cells was increased over the 
average number of invading 2631 cells by a factor of 4.3 (Fig. 3C). 
 
Fig. 3.  CHOP-resistant cells are more invasive. Cross-sectional views of CHOP-
sensitive 2631 and CHOP-resistant G3 invasion in 3-dimensional collagen matrices (A) 
with a magnified view of an invading cell (B) and manual quantification of the average 
number of invading cells (C). White arrows indicate original cell monolayer. Bar=50 
µm.  
 
We next optimized the number of invading cells and the duration of the experiment 
using another CHOP-resistant line derived from 2631 named G2. We decided to use G2 
because its metabolism is slightly slower than G3 and G2 survives longer in the assay 
without requiring change in medium (data not shown). G2 cells invade over the course 
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of 48 h, with the majority of invasion occurring after 24 h (Fig. 4A). The number of cells 
seeded on the gel at the beginning of the experiment was varied to determine if cell 
confluence was required for invasion (Fig. 4B). However, at 48 h there were cells 
navigating the gel, revealing that the cells are inherently invasive. Optimal conditions 
were determined by comparing all cell numbers over the course of 48 h (Fig. 4C).  
 
Fig. 4. G2 invasion assay optimization. (A) Cross-sectional views of invading G2 over 
48 h and (B) top views of various numbers of invading cells on the monolayer are 
summarized (C) for 10-200K cells over 48 h (C). White arrows indicate original cell 
monolayer and black arrows indicate invading cells. Bar=100 µm.  
 
 
For the greatest sensitivity, we wanted to select the conditions that resulted in the 
greatest number of invading cells. While both 100K and 200K seeded cells followed 
48h 36h 24h 12h 0h 
A 
B 
200K 100K 50K 20K 10K 
C 
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similar invasion responses for the first 36 h, 100K had the greatest number of invading 
cells at 48 h. The decrease in invasion for 200K at 48 h is likely due to overconsumption 
of nutrients or accumulation of metabolic waste. Subsequent experiments were 
conducted by seeding 100K cells and allowing 48 h for invasion. 
 
To determine a suitable fluorescent compound for quantification, we investigated several 
cellular dyes and markers (Fig. 5A). We selected a membrane stain (toluidine blue), a 
fluorescent membrane stain (DiI), a fluorescent nuclear stain (DAPI), a fluorescent-
conjugated analogue of tomato lectin, a fluorescent cytosolic protein marker (CT488) 
and a metabolic dye resazurin (Alamar Blue ®). 
 
Fig. 5. Quantification of G2 invasion with various cellular dyes. (A)Various cellular 
dyes tested and (B) normalized quantification for 0K, 50K, and 200K cells in collagen 
gels. (C) Resazurin sensitivity for a 0K-100K cell curve. 
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Initial experiments for each dye tested their ability to accurately detect cell numbers and 
differentiate between 0, 50K, and 200K cells already present in the gel (Fig. 5B). Initial 
experiments determined that labeling the cells before placing them on the gels inhibited 
invasion and was not ideal for studying metastasis (data not shown). Ideally, increasing 
cell numbers should demonstrate increased signal without significant overlap. Toluidine 
blue absorbance was not a good candidate due to high variability and low sensitivity. DiI 
and lectin were unable to permeate the gel and stain the cells after the invasion assay 
(data not shown), resulting in minimal changes in fluorescent signal with increasing cell 
numbers. DAPI fluorescence was indistinguishable by the plate reader. CT488 
demonstrated the correct signal trends; however, there was significant overlap in signal 
indicating high variability and insufficient sensitivity. Resazurin showed considerable 
sensitivity for smaller differences in cell numbers (Fig. 5C) without significant overlap, 
making it a prime candidate for automated quantification. 
 
After investigating fluorescent cell markers, we transfected G2 with GFP, a benign 
fluorescent protein. After transfecting and establishing a stable culture resistant to 
blasticidin, we sorted cells based on their level of GFP expression by fluorescence-
activated cell sorting (FACS) using a FACS-Aria II (Fig. 6A). We sorted and collected 
the 3.8% brightest GFP-expressing cells and photographed cells under phase (Fig. 6B) 
and UV light (Fig. 6C).  
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Fig. 6. Isolation of G2-GFP. Stable GFP-expressing G2 were (A) isolated with a FACS-
Aria II and compared under (B) phase and (C) UV light. Arrows indicate the same cell 
visible under normal light and GFP fluorescence. 
 
Despite successful isolation of GFP-positive cells, invasion experiments with the G2-
GFP cells demonstrated that the GFP signal was not intense enough to register on the 
platereader (data not shown). 
 
Based on encouraging results from the fluorescent metabolic dye resazurin (Alamar 
Blue®), we decided to optimize conditions to quantify invasion.  From our previous dye 
experiments, we determined that initial experiments should determine the ability of the 
dye to permeate the collagen gel and reflect cell numbers. After verifying the ability of 
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Alamar Blue to penetrate the gel, we conducted experiments to optimize resazurin 
concentration for 0-100K cells already present in the gel (Fig 7A).  
 
Fig. 7. Optimization of resazurin quantification. Resazurin incubation was (A) optimized 
for concentration and (B) compared with a manual count to verify accurate reflection of 
invasion for 2631, G2, and G3. (C) Fluorescence and (D) absorbance were analyzed with 
a platereader for a resazurin incubation time course for varying numbers of seeded cells. 
 
 
To maximize sensitivity for differences in fluorescence, we selected 20 µg/ml as the 
working concentration. 1 mg/ml and 100 µg/ml were deemed too toxic and 10 µg/ml did 
not produce the strongest signal for differences between 80K and 100K seeded cells. To 
verify the accuracy of our model, we compared a manual count of 2631, G2, and G3 to 
fluorescence data from an overnight incubation with 20 µg/ml resazurin (Fig. 7B). The 
trend was accurately reflected for all three cell types, although the relative fluorescence-
invasion agreement for G3 was not as sensitive as agreement for 2631 and G2. We 
B A 
C D 
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conducted a time course for resazurin incubation for a cell curve of 0-100K seeded cells 
to optimize the number of seeded cells and resazurin incubation time and determine 
whether quantification via fluorescence (Fig. 7C) or absorbance (Fig. 7D) was more 
sensitive. The trend along the cell curve was consistent for both quantification via 
fluorescence and absorbance between 8 and 24 hours of incubation (absorbance readings 
are inverse of fluorescence readings). Interestingly, the dye becomes saturated when 
processed by 70K or more cells, indicating that there is no benefit to seeding more than 
70K cells under normal conditions. Beyond 24 hours, small differences in the number of 
invading cells are lost due to dye saturation; therefore, the ideal window for 
quantification is between 8 and 24 hours. We determined 16 hours as the most 
convenient incubation period because resazurin can be added in the afternoon, incubated 
overnight, and read on the platereader the next morning. 
 
After optimizing the invasion assay, we investigated the effects of various cytoskeletal 
inhibitors on G2 invasion. Using physiological doses, we added paclitaxel, vincristine, 
vinblastine, colchicine, withaferin A, and cytochalasin D to invading cells after seeding 
them on the gel. From manual quantification of invading cells (Fig. 8A) and cross-
sectional photographs of the wells (Fig. 8B), we discovered that microtubule 
depolymerization with vincristine (1µM), vinblastine (1µM), and colchicine (200nM) 
did not inhibit invasion, whereas microtubule stabilization with paclitaxel significantly 
inhibited invasion (p=0.006) at a physiological dose. Vincristine treatment increased 
invasion (p=0.038). 
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Fig. 8. Effects of cytoskeletal drugs on G2 invasion. (A) Manual quantification and (B) 
cross-sectional photographs of invading cells treated with cytoskeletal drugs . All drug 
concentrations were 1µM except for 200 nM colchicine. * represents a p-value of <0.05, 
** represents a p-value of <0.01 vs. control. Bar=200 µm. 
 
 
Withaferin A, a vimentin depolymerizing agent, and Cytochalasin D, an actin 
depolymerizing agent, both nearly completely inhibited invasion at a concentration of 
1µM (p=0.001). 
 
A 
Control Vincristine Paclitaxel Vinblastine 
Cytochalasin D Withaferin A Colchicine 
B 
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We tested the ability of resazurin to accurately quantify the number of invading cells by 
comparing resazurin data to a manual count for a withaferin dose response (Fig 9).  
Fig. 9. Manual and objective quantification of a withaferin dose curve. A semi-
logarithmic curve of G2 invasion in the presence of withaferin A was quantified by 
manual counting and resazurin quantification.  
 
 
The trends both show a dose-dependent decrease in invasion with increasing withaferin 
A concentration; resazurin sensitivity is apparent between 31.6nM and 100nM, where a 
slight decrease in cells correlated to a significant difference in resazurin signal. 
Additionally, both data sets display flat endpoints above the effective blocking dose of 
1µM. 
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To better understand the nature of lymphoma invasion, we tested the effects of the pro-
proliferation and pro-motility cytokines LPA and S1P in the collagen matrix in the 
presence and absence of a growth factor (GF) mixture of vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), 
and insulin-like growth factor (IGF). We quantified this experiment with our resazurin 
protocol (Fig. 10). 
 
Fig. 10. Effects of growth factors, LPA, and S1P on G2 invasion. LPA and S1P were 
added to the gel before cells were seeded with or without growth factors. * represents a 
p-value of <0.05 vs. GF. ** represents a p-value of <0.01 vs. control without GF. 
 
 
According to these data, the GF mixture had a slight negative, if not negligible, effect on 
lymphoma invasion. 2µM LPA, 1uM S1P, and 2µM S1P inhibited invasion. 
  19 
CHAPTER IV 
SUMMARY AND DISCUSSION 
Summary 
We have designed a lymphoma invasion assay that is objectively quantifiable through 
the use of the cellular dye resazurin; optimal resazurin quantification occurs with 70,000 
seeded cells/well treated with 20ug/ml resazurin for 12-16h. Altogether, this assay 
provides a quantifiable model for lymphoma invasion into 3-dimensional collagen 
matrices mimicking the extracellular matrix. To invade, CHOP-resistant lymphoma cells 
require dynamic tubulin instability and intact vimentin and actin polymers, possibly due 
to a shift in cytoskeletal organization to accommodate the loss of microtubules 
associated with chemotherapy. CHOP-resistant lymphoma are inherently more 
aggressive and does not require growth factors, LPA, and S1P, which are cytokines that 
typically promote cell motility. Applications include metastatic potential, proteomic and 
biochemical analyses, drug screening, and pharmacological studies.  
 
Discussion 
Previous viability assays, such as MTT [18] and MTS [19] assays, are limited to 
colorimetric assays and require additional steps to solubilize the reductase product. Our 
assay removes this requirement and utilizes a one-time addition of resazurin in media 
and the option of quantification by absorbance or fluorescence. With this resazurin 
method, variability due to intermediate solvent additions to solubilize the product and 
their effects on cellular metabolism are avoided. Alamar blue assays have been 
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established for determining cell growth and survival of cancer cells [20] and for 
determining cellular viability after screening with potential drugs [21]. Our assay 
integrates the detection of viable invading cells into an invasion assay, allowing for rapid 
and objective high-throughput screening of potential anti-metastatic drugs and selective 
targeting of factors related to CHOP-resistance. 
 
The cytoskeletal composition of cells is similar to that of a macroorganism. 
Microtublules are large structures that provide the majority of structure and serve as 
anchors for smaller cytoskeletal proteins similar to a skeletal system. Vimentin acts as a 
weaker but more flexible structure akin to cartilage and its role in cellular signaling may 
parallel the nervous system. Actomyosin structures are analogous to cellular muscles and 
are responsible for the contractile physiology of muscle tissue. The results for the 
various cytoskeletal drugs are understandable in this context: an organism must be able 
to physically move itself and have the proper support and signaling for effective 
movement. Successful actin and vimentin polymerization would therefore be required to 
pull the invading cell through the extracellular matrix. As evidenced by invertebrates, 
bones are not a universal necessity. Excessive microtubule stabilization and 
polymerization caused by paclitaxel is likely due to limited flexibility; too many bones, 
hyperostosis, causes the organism to become too rigid and impairs mobility. 
 
Separate studies uncovered a noticeable up-regulation of multiple proteins controlling 
motility in the CHOP-resistant lines and prompted our lab to test whether drug-resistant 
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lines were more invasive in 3-dimensional collagen matrices. Vimentin expression 
increases in endothelial cells during angiogenesis [22] and correlates with a period of 
increased cellular motility. High levels of vimentin expression are associated with 
increased metastasis and a poor prognosis in breast cancer [23], particularly for cancer 
cells resistant to microtubule depolymerizing/DNA intercalating agents [24]. Vimentin 
up-regulation has also been identified as a factor for increased motility in prostate cell 
cancer cells [25]. The exact role of vimentin in cellular motility is still unclear, but some 
research suggests that vimentin mediates matrix adhesion [26]. We theorize that cancer 
cells up-regulate vimentin to accommodate the loss of microtubules associated with 
CHOP therapy. Vimentin fibrils can move rapidly without changing overall cell shape  
[27], a desirable characteristic for more motile cells as they scramble to accommodate 
invasive structures. Conversely, because assembly of vimentin networks is dependent on 
microtubule-associated kinesins [28], loss of microtubule integrity would result in 
ineffective regulation of vimentin polymerization. 
 
Microtubule depolymerization can induce cellular motility [29] and activate Rho-
dependent pathways [30]. Rho-family protein expression has been used as biomarker for 
cancer cells[31-32] and shown to mediate the organization of the actin cytoskeleton , 
enhance motility, and promote degradation of the extracellular matrix[33]. Resistance to 
multiple microtubule depolymerizing agents has been shown to be occur in Chinese 
hamster ovarian cells[34] after treatment with a single agent, indicating the possibility 
that repeated microtubule depolymerization causes a shift in normal dependence on 
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microtubules. Because vincristine is a principle component of CHOP, our data raise the 
possibility that repeated therapy likely contributes to the increased invasion in our 
resistant cell lines. It is therefore imperative to investigate other targets for treating 
lymphoma or discovering compounds that selectively target resistant cell lines. Using 
the method developed here, we can begin to study these events. 
 
As the smallest and most transient cytoskeletal element, actin localization at the 
membrane is essential for the formation of local invadopodia/podosome structures 
required for metastasis [35-36]. In our experiments, actin depolymerization with 
cytochalasin D greatly inhibited the ability for G2 to invade. As evidenced by (Fig. 3B), 
lymphoma are invading by extending portions of the membrane and “stepping” into the 
matrix. Targeting the proteins required for actin localization at the membrane would 
likely be an effective therapy for metastatic cancer.   
 
S1P and LPA increase cellular motility for some types of cancer[37-38], but we have not 
discovered any positive effect of LPA or S1P for lymphoma invasion. S1P and LPA 
insensitivity have been linked to metastatic cancer [39] and S1P/LPA receptors are being 
investigated as treatment for metastatic cancer [40]. LPA has also been identified as an 
indirect inhibitor of matrix metalloproteinases (MMPs) [41], enzymes required for 
digesting the extracellular matrix. MMPs are required for endothelial cell migration [42-
43], but their role in lymphoma metastasis is unclear. MMP localization at the membrane 
and extracellular matrix digestion at the membrane are linked to podosomes and 
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metastasis [44] and Rho-mediated pathways [37].  Long-standing debates theories of 
amoeboid movement continue [45] and several groups doubt the ability for cells to 
navigate the extracellular matrix without degradation [46-47]. We plan to conduct 
invasion experiments with various MMP inhibitors, analyze them using our protocol, 
and investigate the role of collagen degradation in lymphoma invasion. From there, we 
can determine whether or not collagen degradation is required for lymphoma invasion , 
investigate the role of Rho GTPases, and more closely define key elements of 
cytoskeletal signaling that control invasion of drug-resistant lymphoma. 
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